NasdaqGS:PCVXBiotechs
Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?
In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity offering and filing additional shelf capacity linked to employee stock plans.
Alongside these financing moves, the company highlighted unprecedented Phase 2 results for its VAX-31 pneumococcal vaccine, rapid progression into multiple Phase 3 trials, and completion of a large-scale manufacturing...